• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Summit Therapeutics Shares Are Trading Higher By Over 82%? Here Are 53 Stocks Moving In Tuesday's Mid-Day Session

    12/6/22 1:31:35 PM ET
    $ACB
    $AMAM
    $ANEB
    $ATRO
    Medicinal Chemicals and Botanical Products
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ACB alert in real time by email

    Gainers

    • Summit Therapeutics Inc. (NASDAQ:SMMT) shares surged 82.2% to $1.4299 after the company announced a definitive agreement of its partnership with Akeso to in-license its breakthrough bispecific antibody, ivonescimab.
    • Pacifico Acquisition Corp. (NASDAQ:PAFO) gained 51.8% to $7.59.
    • Vivint Smart Home, Inc. (NYSE:VVNT) shares jumped 32.4% to $11.90 after NRG Energy announced it will acquire the company for $12 per share in cash.
    • Studio City International Holdings Limited (NYSE:MSC) gained 28.3% to $4.22. Studio City Intl, last month, posted a Q3 loss of $0.44 per share.
    • Starry Group Holdings, Inc. (NYSE:STRY) shares climbed 23.2% to $0.1725 after dipping more than 20% on Monday.
    • BioSig Technologies, Inc. (NASDAQ:BSGM) rose 23% to $0.5930 after jumping over 15% on Monday. BioSig Technologies, last month, posted a Q3 loss of $0.14 per share.
    • Ra Medical Systems, Inc. (NYSE:RMED) gained 22% to $5.09.
    • Signet Jewelers Limited (NYSE:SIG) surged 19.8% to $69.28 after the company reported better-than-expected Q3 results and issued FY23 guidance above estimates.
    • SCWorx Corp. (NASDAQ:WORX) rose 17.2% to $0.78 after jumping over 18% on Monday.
    • Graphex Group Limited (NYSE:GRFX) gained 15.7% to $1.25.
    • Ballantyne Strong, Inc (NYSE:BTN) jumped 15.4% to $2.85. STRONG/MDI Screen Systems, Inc., a subsidiary of Ballantyne Strong, announced it has signed an exclusive three-year cinema screen supply agreement with Marcus Theatres.
    • Astronics Corporation (NASDAQ:ATRO) shares gained 13.4% to $10.20. The company, last month, posted downbeat quarterly results.
    • Soluna Holdings, Inc. (NASDAQ:SLNH) jumped 13.1% to $0.6503 after the company issued a corporate update.
    • CSP Inc. (NASDAQ:CSPI) gained 13.1% to $9.46 following Q4 results.
    • Powell Industries, Inc. (NASDAQ:POWL) jumped 12.7% to $30.44 after the company reported better-than-expected Q4 results.
    • NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) rose 12.3% to $1.83. NeuroOne successfully completed its feasibility study with its OneRF Ablation System.
    • GitLab Inc. (NASDAQ:GTLB) shares rose 12.2% to $43.00 after the company reported better-than-expected Q3 results and issued FY23 guidance above estimates.
    • Sumo Logic, Inc. (NASDAQ:SUMO) rose 11.7% to $8.06 after the company reported better-than-expected Q3 results and issued strong guidance.
    • VistaGen Therapeutics, Inc. (NASDAQ:VTGN) gained 11.7% to $0.1391 after the company announced the FDA granted Fast Track designation for the development of PH10 for the treatment of major depressive disorder.
    • Bit Brother Limited (NASDAQ:BTB) rose 11.2% to $0.3891.
    • Perfect Corp. (NASDAQ:PERF) gained 9.7% to $6.34. Piper Sandler initiated coverage on Perfect with a Neutral rating and announced a price target of $7.
    • Niu Technologies (NASDAQ:NIU) gained 7.8% to $4.7450.
    • Ambrx Biopharma Inc. (NASDAQ:AMAM) shares rose 7.7% to $0.5598 after gaining 4% on Monday.
    • G-III Apparel Group, Ltd. (NASDAQ:GIII) gained 7.4% to $13.16. G-III Apparel Group CEO Morris Goldfarb bought a total of 250,000 shares at an average price of $12.54.
    • Bionano Genomics, Inc. (NASDAQ:BNGO) rose 7% to $2.1350. Bionano Genomics recently announced plans to acquire Purigen Biosystems for up to $64 million.
    • Mainz Biomed B.V. (NASDAQ:MYNZ) rose 5% to $8.36. Mainz Biomed reported IRB approval and initiation of US pivotal FDA clinical study.


    Losers

    • Gossamer Bio, Inc. (NASDAQ:GOSS) shares dipped 70.6% to $2.7356 after the company reported announced topline results for the TORREY Phase 2 study of seralutinib in patients with pulmonary arterial hypertension (PAH).
    • Barnes & Noble Education, Inc. (NYSE:BNED) dipped 39.8% to $1.5350 after reporting downbeat Q2 earnings.
    • MEI Pharma, Inc. (NASDAQ:MEIP) fell 35% to $0.2543 after the company and Kyowa Kirin reported discontinuation of Zandelisib development outside of Japan following the recent FDA meeting.
    • Winc, Inc. (NYSE:WBEV) dropped 33% to $0.2773. NYSE American announced that the staff of NYSE Regulation determined to commence proceedings to delist the common stock of Winc from the Exchange.
    • Titan Medical Inc. (NASDAQ:TMDI) fell 31.2% to $0.58. Titan Medical implemented cost-cutting measures to support strategic review process.
    • China Automotive Systems, Inc. (NASDAQ:CAAS) dropped 27.8% to $5.67.
    • MMTec, Inc. (NASDAQ:MTC) dipped 27% to $1.0996
    • China Pharma Holdings, Inc. (NYSE:CPHI) declined 21.8% to $0.1274. China Pharma announced the acquisition of Dry Eye Disease Therapeutic Device Project.
    • Sunlands Technology Group (NYSE:STG) dropped 20.3% to $5.98.
    • Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) fell 20% to $4.20. Checkpoint Therapeutics announced a 1-for-10 reverse stock split.
    • Mirati Therapeutics, Inc.. (NASDAQ:MRTX) shares fell 19.1% to $74.92 after the company announced late-breaking results evaluating concurrent adagrasib and pembrolizumab in first-line advanced/metastatic non-small cell lung cancer.
    • Herbalife Nutrition Ltd. (NYSE:HLF) dropped 19.2% to $14.15 after the company announced a convertible senior note offering of $250 million.
    • Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) declined 18.5% to $2.4450.
    • Cosmos Holdings Inc. (NASDAQ:COSM) shares fell 17.7% to $0.4691 after gaining more than 6% on Monday.
    • Digital Brands Group, Inc. (NASDAQ:DBGI) declined 15.7% to $4.3402.
    • BioVie Inc. (NASDAQ:BIVI) fell 14.2% to $4.47 after the company reported results for NE3107 in Parkinson's and Alzheimer's Phase 2 trials.
    • Faraday Future Intelligent Electric Inc. (NASDAQ:FFIE) dropped 14.1% to $0.2570.
    • Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) declined 13.7% to $2.9233. Anebulo Pharmaceuticals, last month, posted a Q1 loss of $0.11 per share.
    • China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) fell 12.6% to $0.6120 after declining around 7% on Monday.
    • Palomar Holdings, Inc. (NASDAQ:PLMR) dropped 11.5% to $52.40.
    • Canopy Growth Corporation (NASDAQ:CGC) fell 10.5% to $3.8650
    • Cyxtera Technologies, Inc. (NASDAQ:CYXT) fell 10.1% to $1.96.
    • Aurora Cannabis Inc. (NASDAQ:ACB) dropped 9.5% to $1.23. Aurora Cannabis recently repurchased $76.1 million principal amount of convertible notes.
    • Stitch Fix, Inc. (NASDAQ:SFIX) declined 9.2% to $3.6610.
    • Snap Inc. (NYSE:SNAP) fell 9% to $9.19.
    • Lucid Group, Inc. (NASDAQ:LCID) dropped 8.9% to $8.59
    • Top Ships Inc. (NASDAQ:TOPS) fell 7.8% to $2.0285. TOP Ships shares dipped more than 50% on Monday after the company priced a 6.8 million unit offering at $2 per unit.

    Also check this out Bitcoin Drops But Remains Above This Key Level; GMX Becomes Top Loser.

    Get the next $ACB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACB
    $AMAM
    $ANEB
    $ATRO

    CompanyDatePrice TargetRatingAnalyst
    Lucid Group Inc.
    $LCID
    3/4/2026$10.00Underperform
    BofA Securities
    GitLab Inc.
    $GTLB
    3/4/2026$28.00Overweight → Neutral
    Piper Sandler
    GitLab Inc.
    $GTLB
    3/2/2026$29.00Buy → Hold
    TD Cowen
    Gossamer Bio Inc.
    $GOSS
    2/24/2026$1.00Outperform → Neutral
    Wedbush
    Gossamer Bio Inc.
    $GOSS
    2/24/2026$0.30Overweight → Equal Weight
    Barclays
    Gossamer Bio Inc.
    $GOSS
    2/24/2026$1.00Outperform → Market Perform
    Leerink Partners
    Snap Inc.
    $SNAP
    2/10/2026$7.30Neutral → Buy
    Arete
    Palomar Holdings Inc.
    $PLMR
    2/9/2026$150.00Outperform
    Evercore ISI
    More analyst ratings

    $ACB
    $AMAM
    $ANEB
    $ATRO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Business Officer Wambeke David J. bought $670,400 worth of shares (1,000,000 units at $0.67) (SEC Form 4)

    4 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Issuer)

    3/3/26 8:49:19 AM ET
    $NMTC
    Medical/Dental Instruments
    Health Care

    Large owner Nerges Joseph R bought $26,366 worth of shares (3,000 units at $8.79), increasing direct ownership by 0.21% to 1,409,075 units (SEC Form 4)

    4 - CSP INC /MA/ (0000356037) (Issuer)

    2/26/26 3:27:13 PM ET
    $CSPI
    EDP Services
    Technology

    Large owner Nerges Joseph R bought $101,525 worth of shares (11,012 units at $9.22), increasing direct ownership by 0.79% to 1,406,075 units (SEC Form 4)

    4 - CSP INC /MA/ (0000356037) (Issuer)

    2/19/26 1:48:39 PM ET
    $CSPI
    EDP Services
    Technology

    $ACB
    $AMAM
    $ANEB
    $ATRO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    June 7, 2024 - FDA Roundup: June 7, 2024

    For Immediate Release: June 07, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced that it has advised the manufacturers of the licensed and authorized COVID-19 vaccines that the COVID-19 vaccines (2024-2025 Formula) for use in the United States should be monovalent (single strain) JN.1 vaccines to more closely match cu

    6/7/24 3:46:22 PM ET
    $GERN
    $SRAX
    $SNAP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Advertising
    Consumer Discretionary

    March 22, 2024 - FDA Roundup: March 22, 2024

    For Immediate Release: March 22, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA issued an emergency use authorization for Pemgarda (pemivibart) for the pre-exposure prophylaxis (prevention) of COVID-19 in certain adults and adolescents (12 years of age and older weighing at least 40 kilograms [about 88 pounds]).  Pemgarda is

    3/22/24 5:02:42 PM ET
    $SNAP
    $SRAX
    Computer Software: Programming Data Processing
    Technology
    Advertising
    Consumer Discretionary

    November 9, 2023 - FDA Approves First Treatment for Patients with Rare Inherited Blood Clotting Disorder

    For Immediate Release: November 09, 2023 Today, the U.S. Food and Drug Administration approved Adzynma, the first recombinant (genetically engineered) protein product indicated for prophylactic (preventive) or on demand enzyme replacement therapy (ERT) in adult and pediatric patients with congenital thrombotic thrombocytopenic purpura (cTTP), a rare and life-threatening blood clotting disorder. “The FDA remains

    11/9/23 2:30:20 PM ET
    $SRAX
    $SNAP
    Advertising
    Consumer Discretionary
    Computer Software: Programming Data Processing
    Technology

    $ACB
    $AMAM
    $ANEB
    $ATRO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BofA Securities resumed coverage on Lucid Group with a new price target

    BofA Securities resumed coverage of Lucid Group with a rating of Underperform and set a new price target of $10.00

    3/4/26 8:38:27 AM ET
    $LCID
    Auto Manufacturing
    Industrials

    GitLab downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded GitLab from Overweight to Neutral and set a new price target of $28.00

    3/4/26 8:35:56 AM ET
    $GTLB
    Computer Software: Prepackaged Software
    Technology

    GitLab downgraded by TD Cowen with a new price target

    TD Cowen downgraded GitLab from Buy to Hold and set a new price target of $29.00

    3/2/26 8:55:30 AM ET
    $GTLB
    Computer Software: Prepackaged Software
    Technology

    $ACB
    $AMAM
    $ANEB
    $ATRO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Barnes & Noble Education Reports Fiscal Third Quarter 2026 Financial Results

    BNC First Day Program Revenue Increases 32.1% Net Income of $6.7 Million and Adjusted EBITDA of $23.6 Million Company to Commence Dividend Program in First Quarter of Fiscal 2027 Virtual Investor Day Scheduled for June 25, 2026 FLORHAM PARK, N.J., March 10, 2026 (GLOBE NEWSWIRE) -- Barnes & Noble Education, Inc. (NYSE:BNED), ("Barnes & Noble Education," "BNED," "the Company," "we," "us," "our"), a leading solutions provider for the education industry, today reported financial results for the fiscal third quarter ended January 31, 2026. Virtual Investor Day Barnes & Noble Education has scheduled a virtual investor day for June 25, 2026. Management will provide an overview of the Com

    3/10/26 4:15:00 PM ET
    $BNED
    Other Specialty Stores
    Consumer Discretionary

    Top Ships Announces Management Estimate of Net Asset Value at $289 Million

    ATHENS, Greece, March 10, 2026 (GLOBE NEWSWIRE) -- TOP Ships Inc. (the "Company"), an international owner and operator of modern, fuel efficient "ECO" tanker vessels, announced today that after taking into account the most recent charter free vessel value estimates from a third party international broker, debt outstanding and cash, management estimates the Company's net asset value ("NAV") as of December 31, 2025 to be $289 million (including the Company's 50% Joint Venture vessel's values, debt and cash). This translates into a NAV of $58.81 per common share (based on number of common shares currently outstanding) and $45.13 per common share on a fully diluted basis (assuming exercise of

    3/10/26 10:15:00 AM ET
    $TOPS
    Marine Transportation
    Consumer Discretionary

    Cosmos Health Enters into LOI to Acquire $11,500,000 Pharmacy Distribution Network; Remains on Track to Deliver 2027 Revenue Guidance of $155,800,000

    CHICAGO, Ill., March 10, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that it has entered into a Letter of Intent ("LOI"), through its wholly owned subsidiary CosmoFarm S.A. ("CosmoFarm"), with respect to the acquisition of an extensive pharmacy distribution network from an established pharmaceutical company serving the Greek market for almost 40 years. The term of the LOI is ninety (90) days from March 6, 2026. The network currently generates approximately €10 million (approximately $11.5 million based on the prevailing EUR/USD exchange rate) in annual gross reve

    3/10/26 9:00:00 AM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    $ACB
    $AMAM
    $ANEB
    $ATRO
    SEC Filings

    View All

    SEC Form 10-Q filed by Barnes & Noble Education Inc

    10-Q - Barnes & Noble Education, Inc. (0001634117) (Filer)

    3/10/26 4:22:57 PM ET
    $BNED
    Other Specialty Stores
    Consumer Discretionary

    Barnes & Noble Education Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Barnes & Noble Education, Inc. (0001634117) (Filer)

    3/10/26 4:20:51 PM ET
    $BNED
    Other Specialty Stores
    Consumer Discretionary

    SEC Form 6-K filed by TOP Ships Inc.

    6-K - TOP SHIPS INC. (0001296484) (Filer)

    3/10/26 10:15:03 AM ET
    $TOPS
    Marine Transportation
    Consumer Discretionary

    $ACB
    $AMAM
    $ANEB
    $ATRO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Li Yan claimed ownership of 292,500 units of American depositary shares and claimed ownership of 6,615,000 units of Class B ordinary shares (SEC Form 3)

    3 - Niu Technologies (0001744781) (Issuer)

    3/6/26 8:01:35 AM ET
    $NIU
    Auto Manufacturing
    Industrials

    New insider Zhou Fion Wenjuan claimed ownership of 119,284 units of American depositary shares (SEC Form 3)

    3 - Niu Technologies (0001744781) (Issuer)

    3/6/26 7:57:14 AM ET
    $NIU
    Auto Manufacturing
    Industrials

    Interim CEO Winterhoff Marc covered exercise/tax liability with 42,925 shares and was granted 89,967 shares, increasing direct ownership by 15% to 355,065 units (SEC Form 4)

    4 - Lucid Group, Inc. (0001811210) (Issuer)

    3/5/26 6:09:54 PM ET
    $LCID
    Auto Manufacturing
    Industrials

    $ACB
    $AMAM
    $ANEB
    $ATRO
    Financials

    Live finance-specific insights

    View All

    Bionano to Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call Webcast on March 23, 2026

    SAN DIEGO, March 09, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that it will host a conference call and live webcast on Monday, March 23, 2026, at 4:30 p.m. Eastern Time to report financial results for the fourth quarter and full year 2025 and to highlight recent corporate progress. Conference Call & Webcast Details Date:Monday, March 23rd, 2026Time:4:30 p.m. ETParticipant Link:Registration – Click hereWebcast Link:Registration – Click here Participants may access a live webcast of the call on the Investors page of the Bionano website. A replay of the conference call and webcast will be archived on Bionano's investor relations website at https://ir.biona

    3/9/26 4:05:00 PM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Powell Industries Announces Three-For-One Stock Split

    HOUSTON, March 06, 2026 (GLOBE NEWSWIRE) -- Powell Industries, Inc. (NASDAQ:POWL) announced today that its Board of Directors has approved a three-for-one forward stock split of the Company's common stock. The Board of Directors also approved a proportionate increase in the number of authorized shares of common stock to accommodate the stock split. The split will be effected through an amendment to the Company's Amended and Restated Certificate of Incorporation. Each shareholder of record as of the close of trading on March 20, 2026 (the "record date") will receive, after the close of trading on April 2, 2026, two additional shares for every one share held on the record date. Subject to fi

    3/6/26 4:01:00 PM ET
    $POWL
    Electrical Products
    Energy

    Next-Generation Platforms Scale Across Energy, Wellness, and Smokeless Consumer Segments

    Issued on behalf of Doseology Sciences Inc.Equity-Insider.com VANCOUVER, BC, March 5, 2026 /CNW/ -- Consumers are voting with their wallets, and zero-sugar is winning. Zero-sugar beverages are driving 6x more dollar growth than regular varieties as buyers actively choose clean-label products with natural sweeteners and functional ingredients[1]. The global market is forecast to expand from $350 billion in 2024 toward $500 billion by 2029, fueled by health-conscious consumers who want naturally functional products without heavy processing[1]. This structural shift is creating validated demand for precision-dosed, portable formats across energy and wellness categories, positioning Doseology Sc

    3/5/26 9:00:00 AM ET
    $HLF
    $NHTC
    $NMTC
    Other Pharmaceuticals
    Health Care
    Consumer Specialties
    Consumer Discretionary

    $ACB
    $AMAM
    $ANEB
    $ATRO
    Leadership Updates

    Live Leadership Updates

    View All

    Barnes & Noble Education Reports Fiscal Third Quarter 2026 Financial Results

    BNC First Day Program Revenue Increases 32.1% Net Income of $6.7 Million and Adjusted EBITDA of $23.6 Million Company to Commence Dividend Program in First Quarter of Fiscal 2027 Virtual Investor Day Scheduled for June 25, 2026 FLORHAM PARK, N.J., March 10, 2026 (GLOBE NEWSWIRE) -- Barnes & Noble Education, Inc. (NYSE:BNED), ("Barnes & Noble Education," "BNED," "the Company," "we," "us," "our"), a leading solutions provider for the education industry, today reported financial results for the fiscal third quarter ended January 31, 2026. Virtual Investor Day Barnes & Noble Education has scheduled a virtual investor day for June 25, 2026. Management will provide an overview of the Com

    3/10/26 4:15:00 PM ET
    $BNED
    Other Specialty Stores
    Consumer Discretionary

    Bionano Symposium 2026 Concluded with 9 Speakers Describing the Breadth of Bionano Solutions and Their Potential for Use on a Large Scale

    SAN DIEGO, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced highlights from the fourth and final day of Symposium 2026. Day 4 featured updates from some of the most advanced and high-volume cytogenetics and molecular pathology laboratories in the United States, Canada and Europe describing how they envision scaling optical genome mapping (OGM), including processing up to thousands of samples per year with automation, multiple OGM systems, and VIA™ software. Other talks covered topics like Bionano's Ionic® system for isolating DNA and RNA for next generation sequencing (NGS) and advanced analytical tools that could be the future of digital cytogenetics

    2/27/26 8:00:00 AM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Cosmos Health Appoints Globally Recognized AI-Driven Drug Discovery and Clinical-Stage Biotech Expert Dr. Dimitrios Iliopoulos to Advisory Board

    CHICAGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced the appointment of Dr. Dimitrios Iliopoulos to its Advisory Board, where he will support the Company's biotechnology initiatives, with a focus on AI-driven drug discovery and clinical-stage therapeutic development. Dr. Iliopoulos is a world-renowned expert in artificial intelligence, drug discovery, and drug development. He currently serves as Co-Founder and CEO of Athos Therapeutics Inc., an AI software and clinical-stage biotechnology company focused on developing precision therapeutics for autoimmun

    2/24/26 12:30:00 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    $ACB
    $AMAM
    $ANEB
    $ATRO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Astronics Corporation

    SC 13G - ASTRONICS CORP (0000008063) (Subject)

    12/12/24 5:27:21 PM ET
    $ATRO
    Military/Government/Technical
    Industrials

    SEC Form SC 13G filed by SCWorx Corp.

    SC 13G - SCWorx Corp. (0001674227) (Subject)

    12/5/24 7:17:43 AM ET
    $WORX
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    SEC Form SC 13G filed by SCWorx Corp.

    SC 13G - SCWorx Corp. (0001674227) (Subject)

    11/26/24 5:02:01 PM ET
    $WORX
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    $ACB
    $AMAM
    $ANEB
    $ATRO
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Insider Analysis: Purchase at Gossamer Bio Inc. on Jun 21

    Gossamer Bio Inc. recently witnessed an insider purchase by COO/CFO Bryan Giraudo, who acquired $59,110 worth of shares consisting of 100,000 units at $0.59 per share. Insider purchases like this can provide valuable insights for investors, indicating confidence from individuals within the company about its future prospects. Examining previous insider transactions, on 2024-03-19, insiders Peterson Caryn and Aranda Richard each sold $5,343 worth of shares at $1.33, leading to a decrease in their direct ownership percentages. Similarly, on 2024-03-28, Hasnain Faheem, Giraudo Bryan, and Christian Waage sold shares worth $26,773, $7,431, and $7,430, respectively, impacting their direct ownershi

    6/21/24 3:17:31 PM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care